Retatrutide, from Soma Pharmaceuticals , is receiving considerable attention as a potential treatment for obesity control . This innovative drug combines the mechanism of a GLP-1 receptor activator and a GIP receptor agonist , intended to not only promote weight loss but also improve related metabolic factors. Early human data have shown promising